Jazz Pharmaceuticals plc (JAZZ) presented positive data from its Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy. The results from the trial were reported by the company on March 26, 2019.
from RTT - Biotech https://ift.tt/2mUrCfi
via IFTTT
No comments:
Post a Comment